


LISTING OF THE CLAIMS

1. (Previously Presented) A method of treating or preventing atypical depression secondary to pain (DSP) in an individual suffering from DSP or at risk thereof, which comprises administering to the individual an effective amount of a dual norepinephrine serotonin reuptake inhibitor (NSRI) or triple reuptake inhibitor (TRI) to alleviate or prevent at least one symptom of atypical depression.
2. (Currently Amended) The method of claim 1 wherein the ~~selective~~ NSRI has an NE: 5-HT reuptake inhibition ratio of about 1:1 to about 50:1.
3. (Currently Amended) The method of claim 1 wherein the ~~selective~~ NSRI has an NE: 5-HT reuptake inhibition ratio of about 1:1 to about 20:1.
4. (Currently Amended) The method of claim 1 wherein the ~~selective~~ norepinephrine (NE)-serotonin (5-HT) reuptake inhibitor (NSRI) is milnacipran:



or stereoisomeric forms, mixtures of stereoisomeric forms, metabolites, or pharmaceutically acceptable salts thereof.

5. (Original) The method of claim 4 wherein the milnacipran is administered at a dosage of between 100 and 400 mg/day.
6. (Original) The method of claim 4 wherein the milnacipran is administered at a dosage of between 100 and 250 mg/day.

7. (Original) The method of claim 1 wherein the inhibitor is administered two or more times per day.
8. (Original) The method of claim 1 wherein the NSRI has NMDA receptor antagonist properties.
9. (Currently Amended) The method of claim 1 wherein the ~~selective~~ norepinephrine (NE)-serotonin (5-HT) reuptake inhibitor (NSRI) does not substantially increase the risk of seizures.
10. (Currently Amended) The method of claim 1 wherein the ~~selective~~ norepinephrine (NE)-serotonin (5-HT) reuptake inhibitor (NSRI) comprises at least two of milnacipran, sibutramine, and an aminocyclopropane derivative.
11. (Withdrawn) The method of claim 1 wherein the inhibitor is a triple reuptake inhibitor blocking uptake of serotonin, noradrenaline, and dopamine.
12. (Previously Presented) The method of claim 1 wherein the DSP comprises atypical depression and either chronic pain or neuropathic pain.
13. (Previously Presented) The method of claim 12 wherein the DSP comprises chronic pain selected from the group consisting of lower back pain, atypical chest pain, headache, pelvic pain, myofascial face pain, abdominal pain, neck pain and chronic pain caused by a disease or condition.
14. (Currently Amended) ~~The method of claim 1~~ A method of treating or preventing atypical depression secondary to pain (DSP) in an individual suffering from DSP or at risk thereof, which comprises administering to the individual an effective amount of a dual norepinephrine serotonin reuptake inhibitor (NSRI) or triple reuptake inhibitor (TRI)

Response to Office Action mailed June 1, 2006

to alleviate or prevent at least one symptom of atypical depression, wherein the DSP comprises atypical depression characterized by mood reactivity and neurovegetative symptoms present for more than about two weeks.

15-18. (Canceled)